CHRS
NASDAQ:CHRS
Coherus BioSciences
- Stock
1.05
+1.94%
0.01
news - Jul 08, 2025 - 17:30
Metastatic Hepatocellular Carcinoma Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
A report by DelveInsight highlights the robust Metastatic Hepatocellular Carcinoma (MHC) pipeline, featuring 20+ pharmaceutical companies and 25+ pipeline therapies. Key developments include clinical trials by Sanofi, Merck, and CStone, with drugs in Phase III, II, and I/II stages targeting advanced hepatocellular carcinoma. The report covers therapeutic assessments, collaborations, and market insights.
barchart.comnews - Jun 30, 2025 - 14:50
TuHURA Biosciences Completes Acquisition of Kineta
TuHURA Biosciences completed the acquisition of Kineta, Inc., adding its Phase 2-ready drug candidate TBS-2025 to its immuno-oncology pipeline. The deal unlocks $12.5 million in PIPE financing and positions TuHURA to initiate a Phase 2 trial of TBS-2025 in combination with a menin inhibitor for NPM1 mutated AML. The acquisition also expands TuHURA's therapeutic focus and ADC technology.
prnewswire.comnews - Jun 20, 2025 - 04:49
Tocilizumab Biosimilar CT-P47 Shows Promise for Rheumatoid Arthritis Self-Administration
A phase 3 study demonstrates that the biosimilar tocilizumab CT-P47, administered via autoinjector, achieves comparable efficacy and safety to reference tocilizumab in patients with moderate-to-severe rheumatoid arthritis. The study highlights the potential of biosimilars to improve access and reduce costs for chronic disease management, though limitations include a small, predominantly female, and White cohort.
centerforbiosimilars.comnews - Jun 18, 2025 - 13:38
Psoriasis Biosimilars Market Key Players Analysis- Merck KGaA,
The psoriasis biosimilars market is valued at $8.5 billion in 2023 and projected to reach $19.3 billion by 2031, growing at a 10.9% CAGR. Key drivers include cost-effective alternatives to originator biologics, regulatory approvals, and increased healthcare accessibility. Challenges include regulatory uncertainty. Major players include Merck KGaA, Coherus BioSciences, and Amgen Inc. Recent developments include Coherus launching YUSIMRY, a biosimilar of Humira, in 2023.
openpr.comnews - Jun 10, 2025 - 14:00
Talking to with patients
Two campaigns, Magnetic Stories by AREA 23 for Siemens Healthineers and Sounds of NPC by Science & Purpose for Coherus BioSciences, are highlighted as innovative approaches to enhancing patient experience in healthcare through immersive storytelling and sound-based diagnostic tools.
pharmalive.comDescription
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripali...Show More
Earnings
Earnings per Share (Estimate*)
Revenue (Estimate*)
*Estimate based on analyst consensus